{{Drugbox
| Verifiedfields = changed
| verifiedrevid = 459437484
| image = Febuxostat.svg

<!--Clinical data-->
| tradename = Uloric, Adenuric<ref name=drugnames>Drugs.com [https://www.drugs.com/international/febuxostat.html Drugs.com international names for febuxostat] Page accessed June 25, 2015</ref>
| Drugs.com = {{drugs.com|monograph|febuxostat}}
| MedlinePlus = a609020
| DailyMedID = Febuxostat
| licence_EU = yes
| licence_US = Febuxostat
| pregnancy_AU = B1
| pregnancy_AU_comment = <ref name="Drugs.com pregnancy">{{cite web | title=Febuxostat (Uloric) Use During Pregnancy | website=Drugs.com | date=22 February 2019 | url=https://www.drugs.com/pregnancy/febuxostat.html | access-date=17 May 2020}}</ref>
| pregnancy_US = N
| pregnancy_US_comment = <ref name="Drugs.com pregnancy" />
| pregnancy_category = 
| legal_AU = <!-- S2, S3, S4, S5, S6, S7, S8, S9 or Unscheduled-->
| legal_CA = <!-- Schedule I, II, III, IV, V, VI, VII, VIII -->
| legal_UK = <!-- GSL, P, POM, CD, or Class A, B, C -->
| legal_US = Rx-only
| legal_EU = Rx-only
| legal_status =  
| routes_of_administration = 口服

<!--Pharmacokinetic data-->
| bioavailability = ≥84% absorbed
| protein_bound = 99.2% to albumin
| metabolism = 通過{{link-en|CYP1A1}}, [[CYP1A2|CYP1A2]], {{link-en|CYP2C8}}, [[CYP2C9|CYP2C9]], {{link-en|UGT1A1}}, {{link-en|UGT1A8}}, {{link-en|UGT1A9}}<ref name="EMA">{{cite web|url=https://www.ema.europa.eu/documents/product-information/adenuric-epar-product-information_en.pdf|title=Adenuric: EPAR – Product Information|publisher=[[European_Medicines_Agency|European Medicines Agency]]|date=2019-08-06}}</ref>
| elimination_half-life = ~5–8 小時
| excretion = Urine (~49%, mostly as metabolites, 3% as unchanged drug); feces (~45%, mostly as metabolites, 12% as unchanged drug)

<!--Identifiers-->
| IUPHAR_ligand = 6817
| CAS_number_Ref = {{cascite|changed|??}}
| CAS_number = 144060-53-7
| ATC_prefix = M04
| ATC_suffix = AA03
| ATC_supplemental =  
| PubChem = 134018
| DrugBank_Ref = 
| DrugBank = DB04854
| ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}}
| ChemSpiderID = 118173
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = 101V0R1N2E
| KEGG_Ref = {{keggcite|correct|kegg}}
| KEGG = D01206
| ChEBI = 31596
| ChEMBL_Ref = {{ebicite|correct|EBI}}
| ChEMBL = 1164729

<!--Chemical data-->
| IUPAC_name = 2-(3-cyano-4-isobutoxyphenyl)-4-methyl-<br />1,3-thiazole-5-carboxylic acid
| C=16 | H=16 | N=2 | Na=  | O=3 | S=1 
| smiles = N#Cc1c(OCC(C)C)ccc(c1)c2nc(c(s2)C(=O)O)C
| StdInChI_Ref = {{stdinchicite|correct|chemspider}}
| StdInChI = 1S/C16H16N2O3S/c1-9(2)8-21-13-5-4-11(6-12(13)7-17)15-18-10(3)14(22-15)16(19)20/h4-6,9H,8H2,1-3H3,(H,19,20)
| StdInChIKey_Ref = {{stdinchicite|correct|chemspider}}
| StdInChIKey = BQSJTQLCZDPROO-UHFFFAOYSA-N
}}'''非布司他'''（Febuxostat）是一种用于治疗[[痛风|痛风]]的药物，而藥品所針對的痛風基本因[[尿酸|尿酸]]水平过高而引起<ref name="AHFS2019">{{Cite web|title=Febuxostat Monograph for Professionals|url=https://www.drugs.com/monograph/febuxostat.html|accessdate=26 February 2019|work=Drugs.com|publisher=American Society of Health-System Pharmacists|language=en}}</ref>。該藥物通過抑制[[黄嘌呤氧化酶|黄嘌呤氧化酶]]，从而减少体内[[尿酸|尿酸]]的产生。該藥的[[給藥途徑|給藥途徑]]為[[口服|口服]]。該藥常见的副作用包括肝脏出現问题、恶心、关节痛和[[皮疹|皮疹]]<ref name="AHFS2019" />等症狀。妊娠或哺乳期婦女不建议服用該藥物<ref name="BNF76">{{Cite book|title=British national formulary : BNF 76|date=2018|publisher=Pharmaceutical Press|isbn=9780857113382|pages=1087|edition=76}}</ref><ref name="FDA2019">{{Cite web|title=Drug Safety and Availability - FDA adds Boxed Warning for increased risk of death with gout medicine Uloric (febuxostat)|url=https://www.fda.gov/Drugs/DrugSafety/ucm631182.htm|accessdate=26 February 2019|date=21 February 2019|work=FDA|language=en}}</ref>。

非布司他于2008年和2009年分别在欧盟和美国被批准用于医疗用途<ref>{{Cite web|title=Adenuric|url=https://www.ema.europa.eu/en/medicines/human/EPAR/adenuric|accessdate=26 February 2019|date=17 September 2018|work=European Medicines Agency - Commission|language=en}}</ref><ref name="AHFS2019" />。2019年，還藥的[[仿制藥|仿制藥]]被監管部門批准，2020年起正式上市<ref>{{Cite web|title=Generic Uloric Availability|url=https://www.drugs.com/availability/generic-uloric.html|accessdate=1 August 2019|work=Drugs.com|language=en}}</ref> <ref>{{Cite web|title=Febuxostat Generic Uloric|url=https://www.goodrx.com/febuxostat|accessdate=15 April 2020}}</ref>。

== 参考文献 ==
{{Reflist}}

[[Category:芳香醚|Category:芳香醚]]
[[Category:腈|Category:腈]]
[[Category:羧酸|Category:羧酸]]
[[Category:噻唑|Category:噻唑]]
[[Category:黄嘌呤氧化酶抑制剂|Category:黄嘌呤氧化酶抑制剂]]
[[Category:抗痛风剂|Category:抗痛风剂]]
[[Category:CAS不正確標誌的條目|Category:CAS不正確標誌的條目]]